Every weekday, CNBC’s Investing Club with Jim Cramer presents the Homestretch, offering investors an actionable update right before the final hour of market trading. As the week began, the S&P 500 saw a slight uptick, predominantly spurred by AI-related technology stocks and the well-known “Magnificent Seven,” particularly Amazon. The tech giant recently secured a significant multiyear agreement with OpenAI, valued at $38 billion in compute capacity, which became a catalyst for its stock performance. Additionally, the Nasdaq, heavily influenced by technology equities, also edged higher.
Cramer’s insights from his Sunday column seem to have influenced the positive trajectory, encouraging investors to focus on individual stock narratives instead of their market share impact. Stocks like Nvidia experienced a noticeable rally, highlighting promising developments in the tech space.
In terms of corporate reorganizations, both Honeywell’s separation from Solstice and DuPont’s separation from Qnity Electronics have completed. Consequently, price targets for the former parent companies will be revised to accommodate the diminished valuations from these splits, and updates for Solstice and Qnity will follow suit. Market analysts are keenly observing Qnity, with five major firms initiating coverage, all assigning buy or equivalent ratings, projecting an average price target of about $113.
On the other hand, Solstice’s shares are expected to experience volatile trading as its investor profile shifts toward a focus on chemicals rather than multi-industry and aerospace investments. Notably, UBS has initiated coverage of Solstice with a buy rating and a price target set at $62, although many are awaiting management’s guidance for future trajectories. The remaining portion of Honeywell, focusing on automation and aerospace, is anticipating a split into two companies by the latter half of next year.
Eli Lilly has been in the spotlight, maintaining a robust post-earnings rally for three consecutive sessions. Following a roughly 3% gain on Monday, the stock has risen approximately 9% since exceeding expectations with its third-quarter earnings report last week. After a significant dip due to competitive pressures from Novo Nordisk, Lilly is now seeing shares rebound to levels not seen since early 2025. The company plans to invest $3 billion in a new manufacturing facility in the Netherlands, aimed at enhancing its production of oral medications, including its GLP-1 treatment, orforglipron. This investment reflects a broader commitment from Lilly, which is allocating tens of billions to bolster its manufacturing capabilities across the globe, suggesting strong confidence in both existing products and those in the pipeline.
Looking ahead, several companies are set to report earnings after the market closes, including Palantir, Him’s & Hers, Goodyear Tire, Clorox, Coterra Energy, and Diamondback Energy. On Tuesday morning, earnings will be released from prominent names like Eaton, Pfizer, Shopify, Uber, Spotify, Ferrari, and Norwegian Cruise Line.
Subscribers to the CNBC Investing Club with Jim Cramer are encouraged to follow trade alerts issued before Cramer executes transactions in his charitable trust portfolio. Cramer adheres to a 45-minute wait time after sending out any trade alerts, and for stocks discussed on CNBC TV, a 72-hour waiting period is observed before any trades are made.
Investors are reminded that participation in the Investing Club is guided by specific terms and conditions, including a disclaimer that no fiduciary duty or specific profit outcome is guaranteed from the information provided.
